St. Petersburg, FL: The daily administration of hemp-derived CBD and THCV (tetrahydrocannabivarin) is associated with clinically significant weight loss, according to placebo-controlled clinical data published in the journal Cannabis.
An investigator affiliated with the biotechnology company Nex Therapeutics assessed the metabolic effects of the concomitant use of THCV and CBD versus placebo in obese adults. Study participants consumed mucoadhesive oral strips containing either cannabinoids or placebo daily for 90 days, with no additional changes to their diet or exercise routine.
Compared to those consuming the placebo, subjects taking THCV and CBD experienced significant weight loss and other metabolic improvements. Most subjects who consumed cannabinoids reported no adverse effects.
The study’s author concluded, “90-day use of once-daily THCV and CBD-infused mucoadhesive strips was associated with clinically significant weight loss, decreases in abdominal girth, systolic blood pressure, and total and LDL cholesterol.”
A 2023 placebo-controlled study reported that diabetic patients who received a sublingual spray containing CBD and THC improved their blood sugar and cholesterol levels. Clinical trial data has also shown that the cannabinoid THCV decreases fasting glucose levels in type 2 diabetics.
Full text of the study, “Weight loss and therapeutic metabolic effects of tetrahydrocannabivarin (THCV)-infused mucoadhesive strips,” appears in Cannabis.